Valo Health develops the Opal Computational Platform, an integrated system that combines machine-learning-driven computational capabilities with patient data to develop therapeutic programs across major disease areas. Using Opal, Valo scientists have identified associations between genetic markers and disease and specific changes in gene activity, initially focusing on oncology, neurodegenerative, and cardiovascular diseases. The company intends to use new funding to scale the Opal platform, for working capital, and for other general purposes. Valo is led by founder and CEO David Berry and was founded by Flagship Pioneering. It is based in Boston, MA, with additional offices in Lexington, MA, San Francisco, CA, Princeton, NJ, and Branford, CT. Financially, the company completed a Series B final close at $300M and has raised over $450M to date, including a $110M investment from Koch Disruptive Technologies. Valo Health develops an end-to-end Opal Computational Platform that integrates human-centric data and AI/ML to speed drug discovery and development. The company leverages a unique dataset of over 125 million patient-years to identify associations between genetic markers and disease. Valo has advanced several preclinical oncology programs (e.g., NAMPT, PARP1, USP28, HDAC3) and focuses on oncology, cardiovascular disease, and neurodegeneration. The company plans continued discovery and development of therapeutic programs and further build-out of its Opal platform. Valo is headquartered in Boston and maintains offices in Watertown, San Francisco, Princeton, and Branford. Financially, it has raised significant capital to support platform and program growth.

Total raised

$300M

Funding rounds

2

Latest round

Series B

Latest activity

Mar 2021